{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:49:55Z","timestamp":1790383795960,"version":"4.1.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-005905"],"award-info":[{"award-number":["MJFF-005905"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-001065"],"award-info":[{"award-number":["MJFF-001065"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF-005905"],"award-info":[{"award-number":["MJFF-005905"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32 GM008042"],"award-info":[{"award-number":["T32 GM008042"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1F30AG077832-01A1"],"award-info":[{"award-number":["1F30AG077832-01A1"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001881"],"award-info":[{"award-number":["UL1TR001881"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001881"],"award-info":[{"award-number":["UL1TR001881"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Aggregation of the protein \u03b1-synuclein (\u03b1-syn) is the histopathological hallmark of neurodegenerative diseases such as Parkinson\u2019s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), which are collectively known as synucleinopathies. Currently, patients with synucleinopathies are diagnosed by physical examination and medical history, often at advanced stages of disease. Because synucleinopathies are associated with \u03b1-syn aggregates, and \u03b1-syn aggregation often precedes onset of symptoms, detecting \u03b1-syn aggregates would be a valuable early diagnostic for patients with synucleinopathies. Here, we design a liganded magnetic nanoparticle (LMNP) functionalized with an \u03b1-syn-targeting peptide to be used as a magnetic resonance imaging (MRI)-based biomarker for \u03b1-syn. Our LMNPs bind to aggregates of \u03b1-syn in vitro, cross the blood-brain barrier in mice with mannitol adjuvant, and can be used as an MRI contrast agent to distinguish mice with \u03b1-synucleinopathy from age-matched, wild-type control mice in vivo. These results provide evidence for the potential of magnetic nanoparticles that target \u03b1-syn for diagnosis of synucleinopathies.<\/jats:p>","DOI":"10.1038\/s41531-025-00918-z","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T14:38:15Z","timestamp":1745419095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Liganded magnetic nanoparticles for magnetic resonance imaging of \u03b1-synuclein"],"prefix":"10.1038","volume":"11","author":[{"given":"Hope","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Balbirnie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi S.","family":"Sta Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Denver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Lepore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mychica","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunni","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilda","family":"Mirbaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedieh","family":"Shahpasand-Kroner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Mekkittikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn J.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romany","family":"Abskharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Sawaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry V.","family":"Vinters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell E.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil G.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally A.","family":"Frautschy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"918_CR1","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","volume":"388","author":"GBD 2015 Disease and Injury Incidence and Prevalence Collaborators.","year":"2016","unstructured":"GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Lond. Engl. 388, 1545\u20131602 (2016).","journal-title":"Lancet Lond. Engl."},{"key":"918_CR2","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic, J. Parkinson\u2019s disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 79, 368\u2013376 (2008).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"918_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/0891988716654985","volume":"29","author":"S Garcia-Ptacek","year":"2016","unstructured":"Garcia-Ptacek, S. & Kramberger, M. G. Parkinson disease and dementia. J. Geriatr. Psychiatry Neurol. 29, 261\u2013270 (2016).","journal-title":"J. Geriatr. Psychiatry Neurol."},{"key":"918_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. Alpha-synuclein in Lewy bodies. Nature 388, 839\u2013840 (1997).","journal-title":"Nature"},{"key":"918_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"918_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrneurol.2012.242","volume":"9","author":"M Goedert","year":"2013","unstructured":"Goedert, M., Spillantini, M. G., Del Tredici, K. & Braak, H. 100 years of Lewy pathology. Nat. Rev. Neurol. 9, 13\u201324 (2013).","journal-title":"Nat. Rev. Neurol."},{"key":"918_CR7","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1242\/jcs.00967","volume":"117","author":"AR Saha","year":"2004","unstructured":"Saha, A. R. et al. Parkinson\u2019s disease alpha-synuclein mutations exhibit defective axonal transport in cultured neurons. J. Cell Sci. 117, 1017\u20131024 (2004).","journal-title":"J. Cell Sci."},{"key":"918_CR8","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00401-007-0313-7","volume":"115","author":"TG Beach","year":"2008","unstructured":"Beach, T. G. et al. Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol. 115, 445\u2013451 (2008).","journal-title":"Acta Neuropathol."},{"key":"918_CR9","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00401-010-0739-1","volume":"120","author":"BN Dugger","year":"2010","unstructured":"Dugger, B. N. & Dickson, D. W. Cell type specific sequestration of choline acetyltransferase and tyrosine hydroxylase within Lewy bodies. Acta Neuropathol. 120, 633\u2013639 (2010).","journal-title":"Acta Neuropathol."},{"key":"918_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/BF00685366","volume":"36","author":"K Kosaka","year":"1976","unstructured":"Kosaka, K., Oyanagi, S., Matsushita, M. & Hori, A. Presenile dementia with Alzheimer-, Pick- and Lewy-body changes. Acta Neuropathol. 36, 221\u2013233 (1976).","journal-title":"Acta Neuropathol."},{"key":"918_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0022-510X(89)90219-0","volume":"94","author":"MI Papp","year":"1989","unstructured":"Papp, M. I., Kahn, J. E. & Lantos, P. L. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J. Neurol. Sci. 94, 79\u2013100 (1989).","journal-title":"J. Neurol. Sci."},{"key":"918_CR12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/RLU.0000000000000766","volume":"40","author":"I Gayed","year":"2015","unstructured":"Gayed, I. et al. The impact of DaTscan in the diagnosis of Parkinson disease. Clin. Nucl. Med. 40, 390\u2013393 (2015).","journal-title":"Clin. Nucl. Med."},{"key":"918_CR13","doi-asserted-by":"publisher","first-page":"108985","DOI":"10.1016\/j.neuropharm.2022.108985","volume":"208","author":"S Roshanbin","year":"2022","unstructured":"Roshanbin, S. et al. In vivo imaging of alpha-synuclein with antibody-based PET. Neuropharmacology 208, 108985 (2022).","journal-title":"Neuropharmacology"},{"key":"918_CR14","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1016\/j.cell.2023.06.004","volume":"186","author":"J Xiang","year":"2023","unstructured":"Xiang, J. et al. Development of an \u03b1-synuclein positron emission tomography tracer for imaging synucleinopathies. Cell 186, 3350\u20133367.e19 (2023).","journal-title":"Cell"},{"key":"918_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42305-3","volume":"14","author":"R Smith","year":"2023","unstructured":"Smith, R. et al. The \u03b1-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases. Nat. Commun. 14, 6750 (2023).","journal-title":"Nat. Commun."},{"key":"918_CR16","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1002\/mds.29186","volume":"37","author":"K Matsuoka","year":"2022","unstructured":"Matsuoka, K. et al. High-contrast imaging of \u03b1-synuclein pathologies in living patients with multiple system atrophy. Mov. Disord. 37, 2159\u20132161 (2022).","journal-title":"Mov. Disord."},{"key":"918_CR17","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1016\/j.neuron.2024.05.006","volume":"112","author":"H Endo","year":"2024","unstructured":"Endo, H. et al. Imaging \u03b1-synuclein pathologies in animal models and patients with Parkinson\u2019s and related diseases. Neuron 112, 2540\u20132557.e8 (2024).","journal-title":"Neuron"},{"key":"918_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2967\/jnumed.111.100784","volume":"53","author":"DSW Djang","year":"2012","unstructured":"Djang, D. S. W. et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J. Nucl. Med. 53, 154\u2013163 (2012).","journal-title":"J. Nucl. Med."},{"key":"918_CR19","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.2967\/jnumed.110.082263","volume":"51","author":"G Segall","year":"2010","unstructured":"Segall, G. et al. SNM practice guideline for sodium 18F-fluoride PET\/CT bone scans 1.0. J. Nucl. Med. 51, 1813\u20131820 (2010).","journal-title":"J. Nucl. Med."},{"key":"918_CR20","doi-asserted-by":"publisher","unstructured":"OECD. \u2018CT scanners, MRI units and PET scanners, 2019 (or nearest year)\u2019, in Health at a Glance 2021: OECD Indicators. https:\/\/doi.org\/10.1787\/0ad92ec3-en (2021).","DOI":"10.1787\/0ad92ec3-en"},{"key":"918_CR21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1021\/nn700400h","volume":"2","author":"KL Hultman","year":"2008","unstructured":"Hultman, K. L. et al. Magnetic resonance imaging of major histocompatibility class II expression in the renal medulla using immunotargeted superparamagnetic iron oxide nanoparticles. ACS Nano 2, 477\u2013484 (2008).","journal-title":"ACS Nano"},{"key":"918_CR22","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.jvs.2014.02.006","volume":"61","author":"MW Winner","year":"2015","unstructured":"Winner, M. W. et al. Iron and noncontrast magnetic resonance T2* as a marker of intraplaque iron in human atherosclerosis. J. Vasc. Surg. 61, 1556\u20131564 (2015).","journal-title":"J. Vasc. Surg."},{"key":"918_CR23","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1182\/blood-2004-10-3982","volume":"106","author":"JC Wood","year":"2005","unstructured":"Wood, J. C. et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 106, 1460\u20131465 (2005).","journal-title":"Blood"},{"key":"918_CR24","first-page":"768","volume":"10","author":"R Abou Zahr","year":"2020","unstructured":"Abou Zahr, R. et al. Real-world experience measurement of liver iron concentration by R2 vs. R2 Star MRI in hemoglobinopathies. Diagn. Basel Switz. 10, 768 (2020).","journal-title":"Diagn. Basel Switz."},{"key":"918_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74968-z","volume":"10","author":"M Obrzut","year":"2020","unstructured":"Obrzut, M. et al. Value of liver iron concentration in healthy volunteers assessed by MRI. Sci. Rep. 10, 17887 (2020).","journal-title":"Sci. Rep."},{"key":"918_CR26","doi-asserted-by":"publisher","first-page":"6674","DOI":"10.1073\/pnas.1117412109","volume":"109","author":"S Serres","year":"2012","unstructured":"Serres, S. et al. Molecular MRI enables early and sensitive detection of brain metastases. Proc. Natl. Acad. Sci. USA 109, 6674\u20136679 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"918_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nnano.2014.254","volume":"10","author":"KL Viola","year":"2015","unstructured":"Viola, K. L. et al. Towards non-invasive diagnostic imaging of early-stage Alzheimer\u2019s disease. Nat. Nanotechnol. 10, 91\u201398 (2015).","journal-title":"Nat. Nanotechnol."},{"key":"918_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.brainres.2018.11.034","volume":"1707","author":"X-G Liu","year":"2019","unstructured":"Liu, X.-G. et al. ScFv-conjugated superparamagnetic iron oxide nanoparticles for MRI-based diagnosis in transgenic mouse models of Parkinson\u2019s and Huntington\u2019s diseases. Brain Res. 1707, 141\u2013153 (2019).","journal-title":"Brain Res."},{"key":"918_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s13205-018-1286-z","volume":"8","author":"NVS Vallabani","year":"2018","unstructured":"Vallabani, N. V. S. & Singh, S. Recent advances and future prospects of iron oxide nanoparticles in biomedicine and diagnostics. 3 Biotech 8, 279 (2018).","journal-title":"3 Biotech"},{"key":"918_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/ajh.21656","volume":"85","author":"M Lu","year":"2010","unstructured":"Lu, M., Cohen, M. H., Rieves, D. & Pazdur, R. FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am. J. Hematol. 85, 315\u2013319 (2010).","journal-title":"Am. J. Hematol."},{"key":"918_CR31","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.2967\/jnumed.116.181362","volume":"57","author":"AS Thakor","year":"2016","unstructured":"Thakor, A. S. et al. Clinically approved nanoparticle imaging agents. J. Nucl. Med. 57, 1833\u20131837 (2016).","journal-title":"J. Nucl. Med."},{"key":"918_CR32","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nature15368","volume":"525","author":"JA Rodriguez","year":"2015","unstructured":"Rodriguez, J. A. et al. Structure of the toxic core of \u03b1-synuclein from invisible crystals. Nature 525, 486\u2013490 (2015).","journal-title":"Nature"},{"key":"918_CR33","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/0092-8674(88)90262-0","volume":"55","author":"M Green","year":"1988","unstructured":"Green, M. & Loewenstein, P. M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55, 1179\u20131188 (1988).","journal-title":"Cell"},{"key":"918_CR34","doi-asserted-by":"publisher","first-page":"16010","DOI":"10.1074\/jbc.272.25.16010","volume":"272","author":"E Viv\u00e8s","year":"1997","unstructured":"Viv\u00e8s, E., Brodin, P. & Lebleu, B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272, 16010\u201316017 (1997).","journal-title":"J. Biol. Chem."},{"key":"918_CR35","doi-asserted-by":"publisher","first-page":"e46775","DOI":"10.7554\/eLife.46775","volume":"9","author":"S Sangwan","year":"2020","unstructured":"Sangwan, S. et al. Inhibition of synucleinopathic seeding by rationally designed inhibitors. eLife 9, e46775 (2020).","journal-title":"eLife"},{"key":"918_CR36","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Biol. Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Biol. Crystallogr."},{"key":"918_CR37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S0076-6879(04)83004-0","volume":"383","author":"CA Rohl","year":"2004","unstructured":"Rohl, C. A., Strauss, C. E. M., Misura, K. M. S. & Baker, D. Protein structure prediction using Rosetta. Methods Enzymol. 383, 66\u201393 (2004).","journal-title":"Methods Enzymol."},{"key":"918_CR38","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","volume":"95","author":"MG Spillantini","year":"1998","unstructured":"Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA 95, 6469\u20136473 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"918_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.14802\/jmd.23213","volume":"17","author":"A Tarutani","year":"2024","unstructured":"Tarutani, A. & Hasegawa, M. Ultrastructures of \u03b1-Synuclein filaments in synucleinopathy brains and experimental models. J. Mov. Disord. 17, 15\u201329 (2024).","journal-title":"J. Mov. Disord."},{"key":"918_CR40","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0896-6273(02)00682-7","volume":"34","author":"BI Giasson","year":"2002","unstructured":"Giasson, B. I. et al. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34, 521\u2013533 (2002).","journal-title":"Neuron"},{"key":"918_CR41","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.brainres.2004.04.034","volume":"1014","author":"RC Brown","year":"2004","unstructured":"Brown, R. C., Egleton, R. D. & Davis, T. P. Mannitol opening of the blood-brain barrier: regional variation in the permeability of sucrose, but not 86Rb+ or albumin. Brain Res. 1014, 221\u2013227 (2004).","journal-title":"Brain Res."},{"key":"918_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42705-5","volume":"14","author":"N Uemura","year":"2023","unstructured":"Uemura, N. et al. Synuclein aggregates amplified from patient-derived Lewy bodies recapitulate Lewy body diseases in mice. Nat. Commun. 14, 6892 (2023).","journal-title":"Nat. Commun."},{"key":"918_CR43","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","volume":"26","author":"H Oakley","year":"2006","unstructured":"Oakley, H. et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer\u2019s disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129\u201310140 (2006).","journal-title":"J. Neurosci."},{"key":"918_CR44","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","volume":"53","author":"Y Yoshiyama","year":"2007","unstructured":"Yoshiyama, Y. et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53, 337\u2013351 (2007).","journal-title":"Neuron"},{"key":"918_CR45","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1523\/JNEUROSCI.2642-12.2013","volume":"33","author":"M Iba","year":"2013","unstructured":"Iba, M. et al. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer\u2019s-like tauopathy. J. Neurosci. 33, 1024\u20131037 (2013).","journal-title":"J. Neurosci."},{"key":"918_CR46","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00401-014-1373-0","volume":"129","author":"S Boluda","year":"2015","unstructured":"Boluda, S. et al. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer\u2019s disease or corticobasal degeneration brains. Acta Neuropathol. 129, 221\u2013237 (2015).","journal-title":"Acta Neuropathol."},{"key":"918_CR47","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-018-0104-4","volume":"557","author":"C Peng","year":"2018","unstructured":"Peng, C. et al. Cellular milieu imparts distinct pathological \u03b1-synuclein strains in \u03b1-synucleinopathies. Nature 557, 558\u2013563 (2018).","journal-title":"Nature"},{"key":"918_CR48","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41586-020-2317-6","volume":"585","author":"M Schweighauser","year":"2020","unstructured":"Schweighauser, M. et al. Structures of \u03b1-synuclein filaments from multiple system atrophy. Nature 585, 464\u2013469 (2020).","journal-title":"Nature"},{"key":"918_CR49","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41586-022-05319-3","volume":"610","author":"Y Yang","year":"2022","unstructured":"Yang, Y. et al. Structures of \u03b1-synuclein filaments from human brains with Lewy pathology. Nature 610, 791\u2013795 (2022).","journal-title":"Nature"},{"key":"918_CR50","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith, I. G. et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89, 88\u2013100 (2017).","journal-title":"Neurology"},{"key":"918_CR51","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1006\/brcg.1996.0039","volume":"31","author":"DP Salmon","year":"1996","unstructured":"Salmon, D. P. et al. Neuropsychological deficits associated with diffuse Lewy body disease. Brain Cognit. 31, 148\u2013165 (1996).","journal-title":"Brain Cognit."},{"key":"918_CR52","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1136\/jnnp.2006.104257","volume":"78","author":"K Mondon","year":"2007","unstructured":"Mondon, K. et al. Visual recognition memory differentiates dementia with Lewy bodies and Parkinson\u2019s disease dementia. J. Neurol. Neurosurg. Psychiatry 78, 738\u2013741 (2007).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"918_CR53","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/brain\/117.4.835","volume":"117","author":"GK Wenning","year":"1994","unstructured":"Wenning, G. K., Ben Shlomo, Y., Magalh\u00e3es, M., Daniel, S. E. & Quinn, N. P. Clinical features and natural history of multiple system atrophy. Brain 117, 835\u2013845 (1994).","journal-title":"Brain"},{"key":"918_CR54","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S1474-4422(03)00662-8","volume":"3","author":"GK Wenning","year":"2004","unstructured":"Wenning, G. K., Colosimo, C., Geser, F. & Poewe, W. Multiple system atrophy. Lancet Neurol. 3, 93\u2013103 (2004).","journal-title":"Lancet Neurol."},{"key":"918_CR55","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/protein\/gzp065","volume":"23","author":"SA Kenrick","year":"2010","unstructured":"Kenrick, S. A. & Daugherty, P. S. Bacterial display enables efficient and quantitative peptide affinity maturation. Protein Eng. Des. Sel. 23, 9\u201317 (2010).","journal-title":"Protein Eng. Des. Sel."},{"key":"918_CR56","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s40478-023-01658-y","volume":"11","author":"M Schweighauser","year":"2023","unstructured":"Schweighauser, M. et al. Cryo-EM structures of tau filaments from the brains of mice transgenic for human mutant P301S Tau. Acta Neuropathol. Commun. 11, 160 (2023).","journal-title":"Acta Neuropathol. Commun."},{"key":"918_CR57","doi-asserted-by":"publisher","first-page":"e2217835120","DOI":"10.1073\/pnas.2217835120","volume":"120","author":"KA Murray","year":"2023","unstructured":"Murray, K. A. et al. Small molecules disaggregate alpha-synuclein and prevent seeding from patient brain-derived fibrils. Proc. Natl. Acad. Sci. USA 120, e2217835120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"918_CR58","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nature23002","volume":"547","author":"AWP Fitzpatrick","year":"2017","unstructured":"Fitzpatrick, A. W. P. et al. Cryo-EM structures of tau filaments from Alzheimer\u2019s disease. Nature 547, 185\u2013190 (2017).","journal-title":"Nature"},{"key":"918_CR59","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"918_CR60","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1109\/42.906424","volume":"20","author":"Y Zhang","year":"2001","unstructured":"Zhang, Y., Brady, M. & Smith, S. Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm. IEEE Trans. Med. Imaging 20, 45\u201357 (2001).","journal-title":"IEEE Trans. Med. Imaging"},{"key":"918_CR61","first-page":"19","volume":"15","author":"SR Barnes","year":"2015","unstructured":"Barnes, S. R. et al. ROCKETSHIP: a flexible and modular software tool for the planning, processing and analysis of dynamic MRI studies. BMC Med. Imaging 15, 19 (2015).","journal-title":"Imaging"},{"key":"918_CR62","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jneumeth.2013.09.021","volume":"221","author":"I Oguz","year":"2014","unstructured":"Oguz, I., Zhang, H., Rumple, A. & Sonka, M. RATS: rapid automatic tissue segmentation in rodent brain MRI. J. Neurosci. Methods 221, 175\u2013182 (2014).","journal-title":"J. Neurosci. Methods"},{"key":"918_CR63","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3389\/fninf.2014.00044","volume":"8","author":"BB Avants","year":"2014","unstructured":"Avants, B. B. et al. The Insight ToolKit image registration framework. Front. Neuroinform. 8, 44 (2014).","journal-title":"Front. Neuroinform."},{"key":"918_CR64","doi-asserted-by":"publisher","first-page":"16187","DOI":"10.1073\/pnas.1301725110","volume":"110","author":"P Kundu","year":"2013","unstructured":"Kundu, P. et al. Integrated strategy for improving functional connectivity mapping using multiecho fMRI. Proc. Natl. Acad. Sci. USA 110, 16187\u201316192 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-00918-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-00918-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-00918-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:09:45Z","timestamp":1745424585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-00918-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["918"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-00918-z","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"11 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.S.E. is SAB chair and equity holder in ADRx, Inc.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}